Nevertheless, to the best of our knowledge, this is the first study to investigate the relationship between MET- or FDG-PET and alterations in driver genes, including EGFR, PTEN, NF1, and CDKN2A/B in gliomas. This evidence concerns the gene CDKN2A and central nervous system cancer.